In conclusion, since PIVKA-II is significantly higher in PC than in benign pancreatic diseases and shows a quite good diagnostic performance compared to CA19-9, CEA and CA 242, its determination could be considered in the clinical management of PC. The gene discussed is CEACAM5; the disease is pachyonychia congenita.